Celltrion Sets Up JV With Nan Fung To Sell Biosimilars In China
Celltrion is pushing into biosimilar market opportunities in China by setting up a joint venture with local player Nan Fung Group. Vcell Healthcare is aiming to market three of Celltrion’s biosimilars as well as exploring setting up a manufacturing plant in China.
You may also be interested in...
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.